Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide.
AffiliationDepartment of Clinical Research, Christie Hospital NHS Trust, Manchester, U.K.
MetadataShow full item record
Abstract6 patients with advanced breast cancer who had failed first and second line endocrine therapies received bromocriptine (1.25-2.5 mg twice daily per os) and octreotide (Sandostatin) via a continuous subcutaneous infusion (200-400 micrograms/24 h) until disease progression. Pre-treatment 24-h profiles of serum lactogenic hormones and their response to standard provocative tests were established and repeated at 2 weeks, and 3 and 6 months (or at tumour progression). Immunoreactive prolactin (ir-PRL), growth hormone (ir-GH) and insulin-like growth factor I (IGF-I) were measured by radioimmunoassay and bioactive lactogenic hormone levels (BLH) were estimated using the Nb2 rat lymphoma cell bioassay. Before treatment all patients showed episodic secretion of ir-PRL, ir-GH and BLH and provocative stimuli resulted in a peak of ir-GH and BLH maximal between 60 and 90 min after injection but no change in ir-PRL. After 2 weeks of treatment, ir-PRL levels were reduced to below the limit of detection in all 6 patients. Peaks of ir-GH and BLH were still apparent, although much reduced. Immunoreactive PRL continued to be profoundly suppressed in 3 of the 4 patients who remained on treatment for 3 to 6 months. Small pulses of ir-GH were still detectable in these patients with which BLH was, again, well correlated. After 2 weeks of treatment, serum IGF-I levels were reduced by 9-54% of the pretreatment values and generally remained suppressed throughout treatment. Clinically, 4 patients did not show disease progression for periods of up to 6 months and side-effects were minimal.
CitationSerum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide. 1993, 29A (2):209-17 Eur. J. Cancer
JournalEuropean Journal of Cancer
- Serum bioactive lactogenic hormone levels in women with familial breast cancer and their relatives.
- Authors: Anderson E, Morten H, Wang DY, Burns P, Birch J, Howell A
- Issue date: 1989 Dec
- Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer.
- Authors: Manni A, Boucher AE, Demers LM, Harvey HA, Lipton A, Simmonds MA, Bartholomew M
- Issue date: 1989 Dec
- Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study.
- Authors: Fredstorp L, Kutz K, Werner S
- Issue date: 1994 Jul
- Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
- Authors: Hunter SJ, Shaw JA, Lee KO, Wood PJ, Atkinson AB, Bevan JS
- Issue date: 1999 Feb
- The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.
- Authors: van der Lely AJ, Harris AG, Lamberts SW
- Issue date: 1992 Aug